Improving SARS-CoV-2 variants monitoring in the absence of genomic surveillance capabilities: a serological study in Bolivian blood donors in October 2021 and June 2022

Lucia Inchauste[1], Elif Nurtop[1], Lissete Bautista Machicado[2], Yanine Leigue Roth[3], Shirley Lenz Gonzales[4], Maria Luisa Herrera[5], Katty Mina Villafan[6], Pedro Mamani Mamani[7], Marcelo Ramos Espinoza[8], Juan Carlos Pavel Suarez[9], Juan Cansio Garcia Copa[10], Yitzhak Leigue Zabala[11], Etzel Arancibia Cardozo[12], Pierre Gallian [1,13], Xavier de Lamballerie[1] and Stéphane Priet[1]*

[1] Unité des Virus Émergents (UVE: Aix-Marseille Univ – IRD 190 – Inserm 1207), Marseille, France

[2] Programa Nacional de Sangre, Ministerio de Salud y Deportes, La Paz, Bolivia

[3] Banco de Sangre de Referencia Departmental de Beni, Beni, Bolivia

[4] Banco de Sangre de Referencia Departmental de Chuquisaca, Sucre, Bolivia

[5] Banco de Sangre de Referencia Departmental de Cochabamba, Cochabamba, Bolivia

[6] Banco de Sangre de Referencia Departmental de El Alto, El Alto, Bolivia

[7] Banco de Sangre de Referencia Departmental de La Paz, La Paz, Bolivia

[8] Banco de Sangre de Referencia Departmental de Oruro, Oruro, Bolivia

[9] Banco de Sangre de Referencia Departmental de Pando, Pando, Bolivia

[10] Banco de Sangre de Referencia Departmental de Potosí, Potosí, Bolivia

[11] Banco de Sangre de Referencia Departmental de Santa Cruz, Santa Cruz, Bolivia

[12] Banco de Sangre de Referencia Departmental de Tarija, Tarija, Bolivia

[13] Laboratoire de Virologie, Établissement Français du Sang Alpes Méditerranée (EFS), Marseille, France

* Correspondence: stephane.priet@univ-amu.fr; +33(0)4 13 73 21 51

Abstract

Unlike genomic data, serological data have not been previously leveraged to evaluate the SARS-CoV-2 variants circulation. In Bolivia, sustained genomic surveillance capacities were lacking especially at the beginning of the pandemic. In 2021 and 2022 we estimated the prevalence of anti-SARS-CoV-2 antibodies in Bolivian blood donors and explored the feasibility of using virus serum neutralization data for variants thought to have circulated to map their circulation across all departments over a year-long follow-up period. Anti-S1 and anti-NCP SARS-CoV-2 IgGs were studied, along with virus neutralization tests for ancestral-D614G, Gamma, Delta, and Omicron BA.1 lineages of SARS-CoV-2. Between 2021 and 2022, the overall prevalence of anti-S1 and anti-NCP antibodies increased reaching values over 90%, demonstrating that a large proportion of the Bolivian population was no longer naïve to the virus. Viral neutralization data, analyzed through multiple approaches, revealed the spread of the Gamma variant up to 2021, particularly impacting northern departments. In 2022, Gamma continued to circulate in southernmost departments of the country and the emergence of Omicron BA.1 was detected. These trends align with publicly available genomic data from neighboring countries. Our serological analyses successfully identified both new antigenic groups, such as Omicron BA.1, and individual variants related to previously circulating groups, such as Delta. The study contributes insights into overall population immunity to SARS-CoV-2 and variant-specific immunity levels across different regions of Bolivia. It also emphasizes the potency of seroprevalence studies in informing public health decisions and underscore their value in capturing the initial phases of emerging epidemics when variant diversity is limited, facilitating timely genomic surveillance setup.

Keywords: SARS-CoV-2 variants circulation, Infectious disease, Seroprevalence, Neutralizing Antibodies, Public health, Latin America, SARS-CoV-2 surveillance, Decision making.

Introduction

Low- and middle-income countries in the Latin American region are vulnerable to health crises due to a combination of factors such as poverty, fragile political and health systems, persistent and pervasive inequality in income, health care, and education, among others[1]. The SARS-CoV-2 pandemic started in South America with the detection of the first case on February 26, 2020, at São Paulo, Brazil[2]. Although it was initially thought that the pandemic would have less of an impact on this region due to its younger population structure, the pandemic eventually had a significant impact, accounting for 25% of infections worldwide[3].

Seroprevalence studies are a valuable adjunct to active surveillance because they allow analysis of the level of immunity of a population to a specific pathogen without the need for prospective testing, and also provide information on the frequency of cases that do not attract medical attention (asymptomatic infections)[4]. During the first years of the SARS-CoV-2 pandemic, a few South American population-based seroprevalence studies were conducted in Colombia, Perú, Chile, and Brazil[5-11]. Reported seroprevalence values varied through time and geographical location. Notably, high prevalence was observed in locations such as Iquitos-Perú (70%) or Manaus-Brazil (54%) after the first wave[6,10]. However, an unexpected violent second wave occurred concomitantly with the emergence of the Gamma variant, despite the high levels of seroprevalence reported earlier[10-12]. Despite the serious impact of COVID-19 on public health in Bolivia, research studies are still lacking: one study reported a seroprevalence of 43.4% in January 2021 among healthcare workers in the city of Cochabamba[13], but no nationwide seroprevalence study is currently available.

To date, the circulation of SARS-CoV-2 variants has mainly been studied through molecular surveillance, giving the proportion of circulating variants in real time. Therefore, genomic surveillance and serology offer distinct yet complementary insights thus far. However, in countries without significant genomic surveillance capabilities at the start of the epidemic, it has become difficult to assess the spread and impact of variants. Here, we have attempted to reconstruct parts of the history of the spread of SARS-CoV-2 in Bolivia by studying the prevalence and specific neutralizing capacity of anti-SARS-CoV-2 antibodies in blood donors from all Bolivian departments after the second and third COVID-19 waves. Based on the results obtained, we discuss the potential contribution of seroprevalence and seroneutralization studies of viral variants and their complementarity with viral genomics data during the different phases of dissemination of a pathogen such as SARS-CoV-2.

Methods

Background

In Bolivia, the first case of SARS-CoV-2 was reported on March 10th, 2020, and to date 1 209 619 cases and 22 407 deaths have been reported[14]. As for the rest of South America, Bolivia has experienced five waves of SARS-CoV-2 cases: the initial wave (May-September 2020), followed by a second (January-July 2021), a third (December 2021 to February 2022), a fourth (June-August 2022) and the most recent (November 2022 to January 2023). Data on variants circulating in each wave in South America is available in several free-access databases (*e.g.,* the PAHO dashboard) but Bolivian genomic data are scarce and only few sequences have been deposited[15-17].

During the first wave, COVID-19 cases in Bolivia neighboring countries were due to ancestral and D614G SARS-CoV-2 strains (Supplementary Figure S1)[15-17]. ***During the second wave,*** Alpha, Gamma, Lambda and Mu variants were the main types identified, with variable distribution among countries. In contrast to Europe, the Alpha variant was not the most prevalent in any country of South America. Moreover, no specific wave was produced and no associated increase in mortality was observed due to the circulation of the Delta variant. ***The start of the third wave***, as in the rest of the world, was concomitant with the emergence and spread of the Omicron (BA.1) variant. ***The next two waves*** were mainly caused by the Omicron variants BA.2/BA.5 and BQ.1/XBB, respectively.

Specimens and ethical considerations

Samples were collected from volunteer blood donors that agreed to participate in the study and provided written consent. The study was approved by the ethics committee of the Dr. Mario Ortíz Suárez hospital, Santa Cruz de la Sierra, Bolivia (N° FWA0002686) and by the National Blood Program from the Ministry of Health and Sports of Bolivia. Sampling was conducted in close collaboration with the National Blood Program and each Departmental Reference Blood Bank. A first batch of 4238 serum samples was collected between August 26, and October 04, 2021. Samples were obtained from all Departmental Reference Blood Banks of Bolivia, which included the cities of Beni (N=733), Chuquisaca (N=294), Cochabamba (N=500), La Paz (N=500), El Alto(N=500), Oruro (N=500), Pando (N=414), Potosí (N=197), Santa Cruz (N=600), Tarija (N=500). A second batch was collected between May 30 and June 23, 2022,

including a total of 1161 sera from the Departmental Reference Blood Banks of Cochabamba (N=212), La Paz (N=264), Santa Cruz (N=186) and Tarija (N=499).

Vaccination coverage

Vaccination campaign against SARS-CoV-2 in Bolivia started on January 29, 2021[18]. Following the SAGE recommendations, vaccination started for the healthcare workers, then extended to the elderly, and people living with underlying health conditions and later expanded to the general population. Vaccines distributed in Bolivia included the mRNA vaccines Comirnaty (Pfizer-BioNTech) and mRNA-1273 (Moderna), the inactivated virus vaccines CoronaVac (Sinovac Biotech, China) and BBIBP-CorV (Sinopharm, China), the (adeno)viral vector vaccines Ad26.CoV2.S (Johnson & Johnson), Vaxzevria (AstraZeneca), and Sputnik V (Gamaleya Research Institute of Epidemiology and Microbiology). Administration of a booster dose was started on October 11, 2021[19].

SARS-CoV-2 vaccination coverage was estimated for both sampling periods (October 27, 2021 and May 30, 2022) based on data reported by the Bolivian Ministry of Health and the Bolivian National Institute of Statistics[20-22]. To calculate vaccination coverage, the number of vaccine doses administered by the Bolivian Ministry of Health was related (by department and nationally) to the total eligible population according to the Bolivian National Institute of Statistics. At the time of the first and second sampling periods, the eligible population included individuals over 18 years of age and over 11 years of age, respectively.

Immunoassays

All serum samples were first screened using the commercial kit Anti-SARS-CoV-2 Quantivac ELISA IgG (Euroimmun) according to manufacturer's recommendations to detect anti-Spike S1 antibodies. Specimens with BAU/mL<25.6, 25.6≤ BAU/mL<35.2, and BAU/mL≥35.2 were considered negative, equivocal and positive, respectively.

Samples were also tested for the presence of anti-NCP SARS-CoV-2 IgG using an in-house qSAT assay, as described elsewhere[23]. Briefly, the CTD domain of the SARS-CoV-2 N protein (EVAg, ref: 100P-03957) was coupled to a MAGPLEX® magnetic microsphere (Luminex Corporation) using the xMAP® Antibody Coupling Kit (Luminex Corporation) following manufacturer's recommendations (60 pmol/10^6 beads). The coupled beads were resuspended

150 and counted on a Countess™ II Automated Cell Counter (Thermo) to a final concentration of
151 $2x10^6$ beads/ml. Samples diluted in Wash Solution (Thermo) at 1/400 were incubated with
152 1,000 coupled beads per well for 1 h at room temperature in a plate shaker protected from light.
153 After two washes, the beads were incubated with R-Phycoerythrin AffiniPure $F(ab')_2$ Fragment
154 Goat Anti-Human IgG $F(ab')_2$ (Jackson ImmunoResearch) for 1 h at room temperature in a plate
155 shaker protected from light. After washing, antigen-antibody reactions were read on an
156 INTELLIFLEX® system (Luminex Corporation) and the results were expressed as median
157 fluorescence intensity (MFI). Cut-off values for each SARS-CoV-2 antigen for the S, RBD and
158 NCP were described elsewhere[23]. The sensitivity and specificity of the *in vitro* assays were
159 described previously[23].

160 For virus Neutralization Tests (VNT), strains from the B.1 (Bav-Pat1/2020 strain [D614G]),
161 P.1 (SARS-CoV-2/2021/JP/TY7-503 strain [Gamma]), B.1.617.2 (SARS-CoV-
162 2/2021/FR/0610 strain [Delta]), and B.1.1.529 (UVE/SARS-CoV-2/2021/FR/1514 strain
163 [Omicron BA.1]) lineages of SARS-CoV-2 were used. Except for Bav-Pat1/2020 strain
164 (courtesy of Prof. Drosten, Berlin), all strains were provided by the European Virus Archive
165 (EVAg) repository (www.european-virus-archive.com). VNTs were performed for samples
166 with a positive or equivocal result in the anti-Spike S1 ELISA as previously described[24]. Four
167 separate VNT assays were performed in duplicate with strains representative of the D614G,
168 Gamma, Delta, and Omicron BA.1 variants. Briefly, the test consisted in mixing 110µL of a
169 serially diluted (from 1/20 to 1/40960) patient serum sample (in DMEM with 1% of
170 penicillin/streptomycin, Non-Essential Amino Acids and Glutamine), with 110µL of a fixed
171 quantity of a given SARS-CoV-2 strain, to reach a final concentration of 0.5 $TCID_{50}$/µL of
172 plasma dilution. This mixture was incubated for 1 hour at 37°C. One hundred µL was then
173 transferred onto a confluent Vero E6 TMPRSS2+ cells monolayer and incubated at 37°C under
174 5% of CO_2. On day 5 post infection, dilutions showing a cytopathic effect (CPE) were
175 considered negative (no neutralization) and those without CPE were considered positive
176 (complete neutralization of the SARS-CoV2 inoculum). The neutralization titer referred to as
177 the highest serum dilution with a positive result. Specimens with a VNT titer ≥ 20 were
178 considered positive.

179

180 **SARS-CoV-2 seroprevalence**

181 Prevalence values for anti-S1 and anti-NCP antibodies, and for neutralizing antibodies (nAbs)
182 against the ancestral D614G (D614G), Gamma (γ), Delta (δ), and Omicron BA.1 (o) variants
183 were calculated using the Prevalence package RStudio version R-4.0.3[25]. Positive or negative
184 status for each sample and every variable was determined using the cut-offs described above.
185 For all variables, number of positive and negative results were used for prevalence computing.

186 Regarding nAbs, prevalence values for each variant (D614G, γ, δ, o) in each department and
187 nationwide were calculated using the regular seropositivity titer cut-off at 20 (samples with a
188 titer ≥20 were considered positive) and an alternative "high level" seropositivity titer cut-off at
189 ≥640.

190

191 **Evaluation of the circulating variants using a "VNT Titers ratio method"**

192 The circulation of variants in Bolivia before October 2021 and June 2022 was first analyzed
193 through the distribution of samples exhibiting titers higher than the D614G ancestral strain for
194 a given variant of interest (γ, δ, o). The base 2 logarithm of VNT titer ratios (log2-ratios) for
195 the following variants pairs was calculated: D614G/Gamma (D614G/γ), D614G/Delta
196 (D614G/δ), D614G/Omicron BA.1 (D614G/o). Negative log2-ratio indicated that the variant in
197 the denominator (γ, δ, o) had a higher titer than D614. A log2-ratio of 0 indicated that both
198 variants presented the same titer. To evaluate the circulation level of γ, δ, and o variants under
199 increasingly stringent conditions, we calculated the proportion of the population with log2-ratio
200 values of ≤0 (variant titer equal to or greater than D614G), ≤-1 (variant titer at least twice that
201 of D614G), and ≤-2 (variant titer at least four times that of D614G) for each department.

202

203 **Quantification of the circulating variants according to antigenic groups**

204 Antigenic mapping of SARS-CoV-2 based on the neutralizing activity of each variant[26-28]
205 enables us to group the ancestral variants D614G, Alpha, Delta, Lambda, and Epsilon in one
206 group (GI), Beta, Gamma, Mu, Iota, and Zeta in a second group (GII), and Omicron and its
207 derivatives into a third group (GIII). To initiate the quantification of the variants circulating in
208 Bolivia, we initially employed a straightforward approach to estimate the percentage of samples
209 in each antigenic group within each department of Bolivia using two different methods (the
210 "Average titer method" and the "Variant assignment method").

211 *Average titer method*

212 To assess the neutralizing response across distinct antigenic groups, we used the average VNT
213 titer for the D614G and Delta variants to delineate antigenic group I (GI). Antigenic group II
214 (GII) was established based on the VNT titer for the Gamma variant, while antigenic group III
215 (GIII) was defined by the VNT titer for the Omicron BA.1 variant. For evaluating the
216 percentage of each antigenic group within different regions of Bolivia, GI was considered
217 dominant if its titer surpassed those of GII and GIII. Similarly, GII was considered if its titer
218 exceeded those of GI and GIII, and GIII was considered if its titer equaled or surpassed those
219 of GI and GII. Additionally, the prevalences of GI (from ancestral, Alpha, Delta, Lambda, and
220 Epsilon variants), the prevalences of GII (from Beta, Gamma, Mu, Iota, and Zeta variants), and
221 the prevalences of GIII (from all Omicron-derived variants) were obtained for neighboring
222 countries of Bolivia using publicly accessible genomic data when available.

223 *Variant assignment method*

224 **Assignment rules**: We implemented several rules taking into account the previously described
225 decrease in neutralizing activity of variants[26-28] to determine which of the four variants tested
226 was expected to be responsible for the main or last infection (Supplementary Figure S2). Main
227 rules relied on D614G/γ, D614G/δ, and D614G/o log2-ratios to differentiate between D614G,
228 Gamma, Delta, and Omicron variants. Given that Tarija had the lowest variant circulation level
229 and the highest vaccination coverage among the departments analyzed as October 2021, this
230 department was chosen as a reference for establishing the D614G cut-off values for the
231 subsequent rules defining the infection by γ, δ and o variants. Given that approximately 90% of
232 the population in this department exhibited D614G/γ, D614G/δ, and D614G/o log2-ratios ≥0,
233 ≥0, and ≥1 respectively, the D614G variant was assigned to compliant samples. If any of these
234 log2-ratios fell below these threshold values, the corresponding variant (γ, δ, or o) was assigned.
235 Secondary rules were applied on a fraction of samples when the log2-ratios for two pairs were
236 below the threshold values. Additional log2-ratios for Delta/Gamma (δ/γ), Gamma/Omicron
237 BA.1 (γ/o) and Delta/Omicron BA.1 (δ/o) pairs were thus considered to differentiate between
238 the two variants. If both the D614G/γ and D614G/δ log2-ratios were ≤ -1, a δ/γ log2-ratio ≤ 0
239 was chosen to indicate a Gamma infection, while a δ/γ log2-ratio ≥ 1 indicated a Delta infection.
240 When the D614G/o log2-ratio was ≤ 0 and the D614G/γ log2-ratio was also ≤ -1, a γ/o log2-
241 ratio ≥ 1 indicated a Gamma infection; otherwise (γ/o log2-ratio ≤ 0) Omicron BA.1 was
242 assigned. Similarly, if the D614G/o log2-ratio was ≤ 0 and the D614G/δ log2-ratio was ≤ -1, a
243 δ/o log2-ratio ≥ 1 suggested a Delta infection; otherwise (δ/o log2-ratio ≤ 0) Omicron BA.1 was
244 assigned.

245 **Quantification according to assignment rules**: Variants assigned as D614G and Delta were
246 grouped in the antigenic group I, Gamma was set as the antigenic group II, and Omicron BA.1
247 as the antigenic group III. The percentage of samples in each antigenic group were calculated
248 for all departments for each sampling period.

249

250 **Quantification of the circulating variants according to individual variants**

251 The percentage of samples assigned through the Assignment Rules (*cf. supra*) to D614G,
252 Gamma, Delta or Omicron BA.1 was calculated for all departments for each sampling period.

253

Results

Population studied

A first sampling was carried out in blood donors from all Bolivian departments from August 26 to October 4, 2021, after the second epidemic wave (Supplementary Figure S1). A second sampling to follow the evolution of the virus 6 months later was carried out in the 3 most populated departments as well as in the most southern department (May 30 to June 23, 2022, corresponding to the phase before the fourth wave).

Among the 4738 blood donors included for the first period, age ranged from 18 to 64 years, with a median of 29 years (IQR, [23-37]). In the second period, 1161 blood donors were included, ranging in age from 18 to 82 years, with a median of 32 years (IQR, [25-41]). There was a balanced distribution of males (41.9% and 44.4%) and females (58.1% and 55.0%) for both periods.

Vaccination coverage

Vaccination coverage data obtained from the Bolivian Ministry of Health are summarized in Supplementary Figure S3 for both periods with respect to vaccination coverage for the first dose, 2 doses and a booster (3 doses).

In October 2021, the vaccination coverage of the Bolivian population with a first dose ranged from 47.6% (Potosí) to 70.3% (Tarija), reaching 59.3% at the national level. Coverage for the complete vaccination schedule (referred as two doses) varied from 38.4% (Pando) to 61.4% (Tarija), with a national average of 50.1%. The proportion of people who received one boost was very low, ranging from 0% (Pando) to 4.5% (Cochabamba), with a national average of 3.2%.

In May 2022, the coverage for one dose increased significantly, ranging from 62.3% (Pando) to 84.3% (Tarija), with a national average of 76.5%. Full vaccination coverage (2 doses) reached 46.6% (Pando) to 72.9% (Tarija), or 63.8% nationally. The one boost coverage reached 16.2% nationwide (10.9% (Beni) to 22.4% (Tarija)). Compared to the first sampling period, regions with higher (Tarija) and lower (Pando) vaccine coverage remained the same.

Anti-SARS-CoV-2 Spike S1 and -NCP antibody prevalence

284 The anti-SARS-CoV-2 Spike S1 (anti-S1) antibody levels were assessed in each department for
285 both sampling periods (Figure 1A and 1C).

286 In October 2021, at the national level, anti-S1 seroprevalence was 86.3% (95%CI: 85.3 – 87.6)
287 and varied from 77.2% (Beni) to 92.4% (Potosí). Seroprevalence increased to 97.1% (95%CI:
288 95.9–97.9) by June 2022, ranging from 96.6% (Tarija) to 98.5% (La Paz).

289 In October 2021, the anti-NCP seroprevalence was 60.8% (95%CI: 59.5 – 62.1) at a national
290 level, increasing to 90.2% (95%CI: 88.3 – 91.7) in June 2022 (Figures 1B and 1D).
291 In 2021, anti-NCP seroprevalence spanned from 52.7% (Pando) to 76.1% (Potosí). In 2022, the
292 range extended from 85.5% (Santa Cruz) to 92.8% (Tarija). The anti-NCP antibody prevalence
293 was always lower than anti-S1 antibody prevalence in October 2021 and June 2022. The anti-
294 NCP increase in the 4 regions tested was around 30%, while the anti-S1 increase was 8-13%.

295 The estimated hybrid immunity, based on the prevalence of anti-S1 and anti-NCP antibodies,
296 ranged from 51.4% in Pando to 73.6% in Potosí in 2021. By 2022, this increased to between
297 83.3% in Santa Cruz and 90.6% in Tarija (Supplementary Table 1).

298 **Prevalence of neutralizing antibodies.**

299 *Prevalence of nAbs against D614G*

300 **In October 2021,** the nationwide prevalence of D614G nAbs at cut-offs ≥20 and ≥640 were
301 83.1% and 29.1% (Figure 2 and Supplementary Figure S4), respectively, with a geometric mean
302 titer (GMT) of 159 (Supplementary Figure S5). The prevalence of D614G nAbs using the cut-
303 off ≥20 was consistently high across the entire country, ranging from 76.8% in Cochabamba to
304 90.3% in Potosí. Increasing the cut-off to ≥640 revealed that Pando and Tarija had the highest
305 (45.6%) and lowest (17.7%) prevalence, respectively. The rest of the country showed values
306 ranging between 21.5% and 34.9%.

307 **By June 2022,** D614G nAbs nationwide prevalence increased to 98.5% and 57.7% for the cut-
308 off ≥20 and ≥640 respectively, with a GMT of 556. Prevalence obtained with the cut-off ≥20
309 was high across all tested departments, nearly reaching saturation. Using the cut-off ≥640, the
310 highest prevalence was observed in La Paz (73.2%) and the lowest in Tarija (42.9%).

311 *Prevalence of nAbs against Gamma*

312 **In October 2021**, the nationwide prevalence of Gamma nAbs at cut-offs ≥20 and ≥640 were
313 80.8% and 32.5% respectively, with a GMT of 208, showing a substantial circulation of

Gamma, as expected. The 3 northern departments (Pando, La Paz and Beni) had the highest GMTs, varying between 310 and 352. The lowest and highest values were observed in Tarija (63.7%) and Potosí (91.3%), respectively. Using the “high-level cut-off" (≥640), similar to D614G, the highest prevalence was in Pando (48.1%), and the lowest in Tarija (13.0%).

By June 2022, the nationwide prevalence increased to 97.9% and 64.4% for the regular and high-level cut-offs, respectively, with a GMT of 778. The prevalence for the regular cut-off was above 96.5% across all tested departments. The highest and lowest prevalence values with the high-level cut-off were observed in Cochabamba (68.5%), and La Paz (51.8%), respectively.

Prevalence of nAbs against Delta

In October 2021, despite expectations of low or no circulation of the Delta variant, we found 76.7% and 19.1% prevalence values at cut-offs ≥20 and ≥640 for Delta nAbs, respectively. This reflects the high titers observed for D614G, as the result of cross-neutralization within antigenic Group I. The Delta GMT was 81, compared to D614G (159) and Gamma (208).

By June 2022, the nationwide prevalence increased to 96.9% and 42.0% for the cut-offs ≥20 and ≥640, respectively, with a GMT of 230. The prevalence obtained with the cut-off ≥20 exceeded 86.7% across all tested departments, and the highest and lowest prevalence values with the cut-off ≥640 were found in La Paz (43.9%) and Santa Cruz (34.1%), respectively

Prevalence of nAbs against Omicron BA.1

In October 2021, prevalence for Omicron BA.1 was low (37.9% and 2.1% for the cut-off ≥20 and ≥640, respectively), with a GMT of 23. In the absence of Omicron BA.1 circulation at this time, this prevalence reflects cross-neutralization with D614G and Gamma.

By June 2022, nationwide prevalence increased to 90.7% and 19.9% for the cut-offs ≥20 and ≥640, respectively, with a GMT of 127. The highest prevalence at the cut-off ≥640 was recorded in Tarija (21.1%), and the lowest in Santa Cruz (13.0%).

Evaluation of the circulating variants

This was performed using the "VNT Titers ratio method" (see Methods for details). Increasingly stringent conditions (percentage of individuals in the population with titers of variants equivalent to, twice or four times that of D614G) were tested (Figure 3 and Supplementary Figure S6).

Circulation of Gamma

In October 2021, in the northern part of Bolivia, encompassing the Pando, La Paz, Beni, and Cochabamba departments, the population exhibited the highest percentage of individuals with Gamma titers superior to D614G. Conversely, Tarija (South) showed the lowest percentage. This trend remained consistent across all conditions, including the most stringent ones.

By June 2022, the Gamma variant was more actively circulating in Tarija, Cochabamba, and Santa Cruz. Compared to the first sampling period, this variant was less active in La Paz.

We conclude that the gamma variant circulated mainly in the north of Bolivia before October 2021, then spread to the southern regions of the country.

Circulation of Delta and Omicron BA.1

In October 2021, evidence for the circulation of the Delta and Omicron BA.1 variants was minimal, as expected (Supplementary Figure S1)[15-17].

By June 2022, in contrast, the departments tested displayed an increase in the percentage of the population with Delta and Omicron BA.1 titers superior to D614G. The highest values for both Delta and Omicron BA.1 were found in Tarija and Cochabamba, and the lowest in La Paz and Santa Cruz.

We conclude that there is serological evidence for the circulation of both Delta and Omicron BA.1 variants after October 2021.

Quantification of the circulating antigenic groups

Using two approaches (the "Average titer method" and the "Variant assignment method"), the circulating antigenic groups were quantified (Figure 4 and Supplementary Figure S7). The nAbs responses resulting mainly from vaccination, ancestral, and Delta variants were clustered in group I (GI), and Gamma and Omicron BA.1 were the representatives of groups II (GII) and III (GIII), respectively. These two approaches yielded highly congruent results that were also in agreement with the abovementioned results (Figure 3). Data from the "Average titer method" was exposed in the following section (Figure 4).

Antigenic Group I

372 **In October 2021**, the percentages of GI-associated nAbs (GI-nAbs) spanned from 25.1%
373 (Cochabamba) to 80.9% (Tarija). The southernmost departments (Oruro, Potosí, and Tarija)
374 exhibited the highest values, aligning with genomic prevalence from surrounding countries for
375 which GI variants circulated more in Argentina (74.4%), Chile (57.4%) and Perú (79.4%).

376 **By June 2022,** the percentages of GI-nAbs extended from 30.2% (Tarija) to 79.3% (La Paz).
377 Compared to October 2021, the departments of La Paz and Cochabamba showed an increase in
378 the levels, while Santa Cruz and Tarija exhibited a decrease.

379 *Antigenic Group II*

380 **In October 2021**, the percentages of GII-associated nAbs (GII-nAbs) spanned from 19.1%
381 (Tarija) to 74.9% (Cochabamba). The northern departments (Pando, La Paz, Beni, and
382 Cochabamba) presented the highest levels, which reflects the circulation in neighboring Brazil
383 (80.5%).

384 **By June 2022,** the percentages of GII-associated nAbs (GII-nAbs) spanned from 16.5% (La
385 Paz) to 62.8% (Cochabamba). The southern departments of Santa Cruz and Tarija showed an
386 increase, while the northern departments of La Paz and Cochabamba showed a decrease in this
387 response.

388 *Antigenic Group III*

389 **In October 2021**, no evidence of circulation of GIII variants was observed from GIII-associated
390 nAbs (GIII-nAbs) in Bolivia, or genomic surveillance derived data from surrounding countries.

391 **By June 2022,** the percentages of GIII-nAbs varied from 1.7% (Santa Cruz) to 8.9% (Tarija).
392 GIII-nAbs increased across all tested departments, *i.e*. the method was capable of detecting the
393 emergence of the new antigenic group.

394 **We conclude that** these serological data nicely align with the circulation of each antigenic
395 group in the neighboring countries as computed from accessible genomic surveillance data,
396 particularly at the first sampling period (Figure 4 and Supplementary Figure S1).

397

398 **Quantification of the individual variant circulation**

399 The prevalence of individual variants, assigned through the Assignment Rules was examined
400 across all departments, showing similar trends with the above methods but offering a more

401 accurate assessment of ancestral and Delta variant circulation and possible insights into the
402 weight of vaccination in the generation of ancestral D614G-induced nAbs antibodies (Figure
403 S6 and S7).

404 *Quantification of ancestral D614G related variants circulation*

405 **In October 2021,** Tarija exhibited the highest D614G prevalence, while the northern
406 departments had some of the lowest circulation rates, a pattern consistent with vaccination
407 coverage data (Supplementary Figure S3) and the results observed above.

408 **By June 2022,** the southernmost departments of Santa Cruz, and Tarija, saw a reduction in
409 D614G prevalence. This trend comes with a higher level of Gamma circulation observed in
410 these two departments (see above), further supporting the hypothesis of ongoing Gamma
411 circulation between 2021 and 2022. In the department of Cochabamba, no significant change
412 in D614G prevalence was observed (28.3% in October 2020 to 26.6% in June 2022). In contrast,
413 La Paz experienced a notable surge (+40%) in D614G prevalence, consistently with the
414 antigenic group analysis.

415 *Quantification of Delta circulation*

416 **In October 2021,** a low circulation of Delta was observed in all departments, ranging from
417 1.1% (Pando) to 9.1%(Tarija). As a result, the method was able to detect the appearance of the
418 Delta variant, despite its belonging to the same antigenic group as other variants circulating
419 previously.

420 **By June 2022,** the prevalence of Delta remained stable or decreased across the tested
421 departments, with prevalences ranging between 1.5% (La Paz) and 9.1% (Tarija).

422

423

Discussion

To our knowledge, we are reporting the first serological study of SARS-CoV-2 to be carried out in Bolivia in 2021 and 2022, which included blood donors from all the country's departments. This study enabled us to estimate the level of immunity of the population to SARS-CoV-2 nationwide and in the different regions of the country, thus providing valuable information on the circulation of these variants in Bolivia.

Limitations

Firstly, the study was limited to blood donors in the major cities of Bolivia and may therefore not be fully representative of the populations of the country as a whole. Furthermore, in Bolivia, blood donation is unrewarded, and blood donors appear to be quite representative of the general population. Indeed, routine screening for several infection markers (such as HIV or HBV) is conducted in all donors, and the prevalences of these markers do not differ from those observed in the general population. For example, UNAIDS data highlights a 0.4% HIV prevalence within the Bolivian general population, with significantly higher rates exceeding 25% observed in high-risk groups such as men who have sex with men[29]. Moreover, Sheena *et al.* estimated a 0.6% prevalence of HBsAg in Bolivia in 2019[30]. Bolivian national statistics of National Blood Program of the Ministry of Health and Sports, indicate that between 2019 and 2023, the proportion of HIV- and HBV-reactive units among screened blood donors ranged from 0.26% to 0.41% and 0.16% to 0.25%, respectively (Dr. Lissete Bautista's personal communication).

Secondly, our results are based on serological data and may not be strictly identical to the genomic data from a quantitative point of view, although they are likely to reflect similar trends and distributions (see below). The results could also be influenced by various factors, including significant individual variation in antibody responses, as well as the decline in antibody titers during the first months following infection or vaccination[31-34] and could therefore slightly underestimated. As the complexity of SARS-CoV-2 antigen exposure histories increased among tested individuals, we observed a tendency for serological data to start diverging from genomic data. This suggests, as expected, that the effectiveness of this method would be greater if implemented early in an epidemic when the occurrence of multiple infections with different variants or the administration of varying doses of vaccine in the analyzed population before or after infection (resulting in hybrid immunity) is still limited. However, to mitigate the potential challenges arising from complex antigen exposure, we employed straightforward criteria to

456 identify the variant among the four tested in VNT that exhibited the highest value (cf methods),
457 thereby likely indicating the main or most recent infection and minimizing the influence of
458 cross-neutralization on the final outcomes. In addition, several approaches were used to analyze
459 the results, including quantification of circulating antigenic groups and individual variants,
460 yielding results that were comparable and closely aligned with the genomic data.

461

462

463 *Epidemiological assessment*

464 As of October 2021, our data showed an anti-S1 SARS-CoV-2 seroprevalence of 86.3%,
465 indicating that a large part of the population had immunity against SARS-CoV-2 following
466 infection, vaccination, or both (Figure 1). Comparing the vaccination coverage with the anti-S1
467 antibody prevalence, we can infer that significant viral transmission occurred in the population
468 before October 2021 (Figure 1 and Supplementary Figure S3). These epidemiological data are
469 in agreement with other population-based studies performed on the first half of 2021 in Perú
470 and in the northwest of Brazil that reported high SARS-CoV-2 prevalence (63.6% and 65.0%,
471 respectively)[6,10]. In Bolivia, the prevalence observed a few months later was even higher,
472 suggesting sustained virus circulation. By June 2022, although our sample was limited to four
473 departments, the data show a clear trend towards saturation in the prevalence of anti-S1,
474 suggesting that almost the entire population had been vaccinated and/or infected by that time.
475 With vaccination coverage having increased by around 13% (both for those who had received
476 two doses and those who had received the booster), the significant increase (+31.2%) in the
477 seroprevalence of anti-NCP antibodies indicates that a large proportion of the population has
478 been exposed to the virus between October 2021 and June 2022 (Figure 1). Even if a proportion
479 of newly vaccinated individuals had received an inactivated vaccine likely to generate an anti-
480 NCP response, this cannot explain the observed increase in the prevalence of anti-NCP
481 antibodies[35-37]. This corresponds to the emergence of the Omicron BA.1 variant, which has
482 been shown to cause a high rate of infection worldwide[38,39].

483 Consistently, as of October 2021, the prevalence of nAbs against the ancestral D614G (83.1%)
484 and Gamma (80.8%) variants was very high throughout the country (Figure 2 and
485 Supplementary Figure S4). The 3 northern departments (Pando, La Paz and Beni) were the most
486 exposed to the Gamma variant, as reflected by the highest Gamma GMTs (Supplementary
487 Figure S5). By June 2022, the prevalence of neutralizing antibodies against all variants had

488 increased, reaching values higher than 90%, demonstrating that a large proportion of the
489 Bolivian population was no longer naïve to the virus.

490 When looking at nAbs with high neutralization titers, new variant circulation patterns emerged
491 (Figure 2 and Supplementary Figure S4). Some departments in the northern part of Bolivia,
492 especially Pando, may have suffered a greater impact during the two first waves, since nAbs
493 titers were higher for both the D614G and Gamma variants as of October 2021. To gain further
494 insight into the variant circulation, we proposed additional analyses ("VNT Titers ratio
495 method", "Average titer method", "Variant assignment method"; Figures 3 and 4 and
496 Supplementary Figures S6 to S8).

497 As of October 2021, a higher circulation of GII/Gamma was confirmed in northern Bolivia.
498 Moreover, it is likely that the first two waves had a significant impact on Pando, since (despite
499 having the lowest vaccine coverage in the country) high percentages of nAbs responses to the
500 ancestral D614G and Gamma variants were observed. On the other hand, the southernmost
501 department (Tarija) was probably the least affected, as it had the highest percentage of
502 neutralizing response to ancestral viruses and the lowest to Gamma, which is consistent with
503 its high vaccination coverage (the highest in the country). As for Delta, limited circulation was
504 observed across the country, corresponding to the beginning of its circulation in Latin America
505 (Supplementary Figure S1). As expected, no evidence of Omicron BA.1 was observed.

506 By June 2022, analyses showed that GII/Gamma continued to circulate in southernmost
507 departments (Cochabamba, Santa Cruz, and Tarija). Besides, the high level of nAbs against
508 GII/Gamma, observed in the first sampling period, in the population of La Paz seems to have
509 waned and in the contrary GI/D614G nAbs have risen (+40%). This observation cannot be
510 explained solely by an increase in vaccination coverage (Supplementary Figure S3), since
511 vaccination increased by only 13%. GI/D614G nAbs augmentation could be related to the
512 circulation of another GI variant, such as Lambda (which has circulated in the neighboring
513 country of Perú), or alternatively, the infection by the Delta and/or Omicron BA.1 variant may
514 have boosted the level of pre-existing anti-D614G nAbs in the population[40-43]. This boost of
515 pre-existing Abs phenomenon, known as antigenic sin, has been extensively documented in the
516 context of influenza infections and vaccinations[44,45]. As for Delta, prevalences did not change
517 significantly, between October 2021 and June 2022, reflecting the limited Delta wave in Latin
518 America compared to Europe[46]. Despite a significant global wave of the Omicron BA.1 variant
519 in South America, less than 9% of the Bolivian population tested displayed a neutralizing

520 antibody response against Omicron BA.1. This lower-than-expected nAbs response could be
521 attributed to the possibility that this variant increased the levels of pre-existing nAbs to previous
522 variants[40-43].

523 *Significance of serological results*

524 To assess the significance and robustness of our serological results, we compared the results
525 obtained with the different methods used and with genomic data from neighboring countries.
526 We found that the patterns of circulation of antigenic groups/variants were consistent across the
527 different serological methods used (Figure 4 and Supplementary Figures S7 and S8) and that
528 they nicely aligned with the percentage of each antigenic group/variants in the neighboring
529 countries as computed from accessible genomic surveillance data (Supplementary Figure S1).

530 Serological analyses allowed detecting the emergence of a new antigenic group (*e.g.*, Omicron
531 BA.1), but also of an individual variant related to a previously circulating antigenic group (*e.g.*,
532 Delta). Overall, the accuracy of the mapping seems to have diminished with time, the number
533 of variants that have been circulated, vaccination and the saturation of prevalence estimates. As
534 an example, the prevalence values found for Omicron BA.1 in June 2022 are likely to be
535 underestimated (see Figure 4 and Supplementary Figures S1 and S8). Although the detection
536 of a new antigenic group remained possible in this specific study during the late period of
537 variants circulation, our results argue in favor of the greater usefulness of seroepidemiological
538 studies for documenting the early stages of a new epidemic. This is of great interest because it
539 gives time to set up genomic surveillance in countries with limited sequencing capacity at the
540 start of an epidemic emergence.

541

542 In conclusion, our study represents the first large-scale survey conducted in all the departments
543 of Bolivia, with a follow-up period of almost a year. This has enabled us to document ongoing
544 viral circulation and better characterize the epidemiology of SARS-CoV-2 in Latin America,
545 as well as providing essential information on the successive waves that have occurred in
546 Bolivia. In particular, despite a high prevalence in 2022, which could suggest the development
547 of herd immunity, subsequent waves demonstrate the virus ability to adapt and continue
548 circulating in a population that is no longer naïve. Our results confirm and reiterate that
549 seroprevalence studies are a powerful tool for informing public health decision-making. Our
550 findings strongly support the idea that seroepidemiological studies are valuable for capturing

the initial phases of a new epidemic, giving time for the establishment of genomic surveillance in countries with limited sequencing capacity at the onset of an emerging epidemic.

Conflict of Interest

All the authors declare no competing interests.

Funding Source

This study was supported by the French National Research Institute for Sustainable Development (IRD), the project EMERGEN-PRI #22275 of the ANRS I MIE (INSERM), and the European Union's Horizon 2020 research and innovation program (European Virus Archive Global, grant agreement No. 871029). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Ethical Approval

Samples were collected randomly from volunteer blood donors that agreed to participate in the study. Written consent was obtained from all blood donors. The study was approved by the ethics committee of the Dr. Mario Ortíz Suárez hospital, Santa Cruz de la Sierra, Bolivia (N° FWA0002686) and by the National Blood Program from the Ministry of Health and Sports of Bolivia. Sampling was carefully conducted in close collaboration with the National Blood Program and each Departmental Reference Blood Bank.

Authors Contributions

LI, XdL, and SP conceived the study design. LBM, LI, RFZ, SLG, MLH, MLP, VT, RVFF, JCPS, PAO, YLZ, and EAC coordinated and managed sampling. LI and EN performed the serological assays. LI and SP performed the data curation. LI, XdL, and SP prepared the draft of the manuscript. All the authors have reviewed, contributed and approved the final manuscript.

Acknowledgments

The authors thank all professionals from the Departmental Reference Blood Banks. A special thanks to Dra. Daniela Azurduy, Dra. Vanessa Telleria, Dra. Cecilia Peralta, Dra. Rosario Quintanilla, Dra. Rosa Escalier, Dra. Patricia Achacollo Olmo, Dra. Raquel Verónica Figueredo Flores, Dr.Ronald Flores Zabala, and Dra. Maria Luisa Patón for their support and management

to carry out the sampling for the project. We would also like to thank the collaboration of the Ministerio de Salud y Deportes, the Viceministerio de Gestión del Sistema de Salud and the Dirección de Redes de Servicios de Salud.

References

1. The L. COVID-19 in Latin America: a humanitarian crisis. *The Lancet* 2020; **396**(10261): 1463.
2. Melo CML, Silva GAS, Melo ARS, Freitas AC. COVID-19 pandemic outbreak: the Brazilian reality from the first case to the collapse of health services. *An Acad Bras Cienc* 2020; **92**(4): e20200709.
3. The L. COVID-19 in Latin America-emergency and opportunity. *Lancet* 2021; **398**(10295): 93.
4. Wu KM, Riley S. Simulation-guided design of serological surveys of the cumulative incidence of influenza infection. *BMC Infect Dis* 2014; **14**: 505.
5. Reyes-Vega MF, Soto-Cabezas MG, Cárdenas F, et al. SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru. *EClinicalMedicine* 2021; **34**: 100801.
6. Álvarez-Antonio C, Meza-Sánchez G, Calampa C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. *The Lancet Global Health* 2021; **9**(7): e925-e31.
7. Vial P, González C, Icaza G, et al. Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile. *BMC Infectious Diseases* 2022; **22**(1): 99.
8. Mercado-Reyes M, Malagón-Rojas J, Rodríguez-Barraquer I, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study. *The Lancet Regional Health – Americas* 2022; **9**.
9. Nicolete VC, Rodrigues PT, Fernandes ARJ, et al. Epidemiology of COVID-19 after Emergence of SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020-2021. *Emerg Infect Dis* 2022; **28**(3): 709-12.
10. Buss LF, Prete CA, Jr., Abrahim CMM, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science* 2021; **371**(6526): 288-92.
11. Prete CA, Buss LF, Buccheri R, et al. Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil. *BMC Infectious Diseases* 2022; **22**(1): 127.
12. Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. *The Lancet* 2021; **397**(10273): 452-5.
13. Saba Villarroel PM, Castro Soto MdR, Undurraga V, et al. High SARS-CoV-2 Prevalence among Healthcare Workers in Cochabamba, Bolivia. *Viruses* 2022; **14**(2): 232.
14. WHO. WHO Coronavirus (COVID-19) Dashboard. 2023. https://covid19.who.int/ (accessed 13/11/2023.
15. PAHO. SARS-CoV-2 Variants Tracking in the Region of the Americas. 2023. https://ais.paho.org/phip/viz/SARS_CoV2_variants_regional.asp (accessed 13/04/2023.
16. GISAID. Phylodynamics of pandemic coronavirus in Latin America and the Caribbean. 11/04/2023. https://phylodynamics.pandemicprepardness.org/dist/start.html?id=TGF0aW4lMjBBbWVyaWNh&s=1&h=0 (accessed 13/04/2023).
17. Hodcroft E. CoVariants. 12/04/2023 2023. https://covariants.org/ (accessed 13/04/2023.
18. Bolivia MdSyDd. Inicia El Proceso de Vacunación Al Personal de Salud Que Lucha en Primera Línea Contra la Pandemia. 2021. https://www.minsalud.gob.bo/5230-inicia-proceso-vacunacion (accessed 17/04/2023.
19. Bolivia MdSyDd. Salud Dispone 800.000 Vacunas Para Inmunizar Con Dosis Adicional A Mayores De 60 Años Y Con Patologías De Base. 2021. https://www.minsalud.gob.bo/6104-salud-

626 dispone-800-000-vacunas-para-inmunizar-con-dosis-adicional-a-mayores-de-60-anos-y-con-
627 patologias-de-base (accessed 02/05/2023.
628 20. Bolivia MdSyDd. Reporte de Vacunacion Contra la COVID-19 al 30 de Mayo de 2022. 2022.
629 https://www.minsalud.gob.bo/6729-covid-19-salud-informa-que-esta-jornada-se-aplicaron-10-393-
630 dosis-en-el-pais-y-casos-positivos-llegan-a-203 (accessed 02/05/2023.
631 21. Bolivia MdSyDd. Reporte de vacunacion contra la COVID-19 al 27 de octubre 2021. 2021.
632 https://www.minsalud.gob.bo/6163-covid-19-hasta-hoy-la-inmunizacion-alcanza-a-7-650-594-
633 vacunas-aplicadas-con-primeras-segundas-unidosis-y-tercera-dosis (accessed 02/05/2023.
634 22. INE. Población Y Hechos Vitales; Proyecciones de Población, Revisión 2020. 2023.
635 https://www.ine.gob.bo/index.php/censos-y-proyecciones-de-poblacion-sociales/ (accessed
636 02/05/2023.
637 23. Inchauste L, Nurtop E, Brisbarre N, Gallian P, de Lamballerie X, Priet S. Exploring cell-free assays
638 for COVID-19 serosurvey. *Submitted* 2023.
639 24. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of
640 antibodies neutralizing SARS-CoV-2 in group O French blood donors. *Antiviral Res* 2020; **181**: 104880.
641 25. Devleesschauwer B, Torgerson P, Charlier J, et al. Package 'prevalence'. 2013.
642 26. Mykytyn AZ, Rissmann M, Kok A, et al. Antigenic cartography of SARS-CoV-2 reveals that
643 Omicron BA.1 and BA.2 are antigenically distinct. *Sci Immunol* 2022; **7**(75): eabq4450.
644 27. Wilks SH, Muhlemann B, Shen X, et al. Mapping SARS-CoV-2 antigenic relationships and
645 serological responses. *Science* 2023; **382**(6666): eadj0070.
646 28. van der Straten K, Guerra D, van Gils MJ, et al. Antigenic cartography using sera from sequence-
647 confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron.
648 *Immunity* 2022; **55**(9): 1725-31 e4.
649 29. UNAIDS. Country factsheets BOLIVIA (PLURINATIONAL STATE OF) 2022 2022.
650 https://www.unaids.org/en/regionscountries/countries/bolivia (accessed 03/04/2024.
651 30. Sheena BS, Hiebert L, Han H, et al. Global, regional, and national burden of hepatitis B,
652 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*
653 *Gastroenterology & Hepatology* 2022; **7**(9): 796-829.
654 31. Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to
655 the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Sci Immunol* 2020;
656 **5**(52).
657 32. Hartley GE, Edwards ESJ, Aui PM, et al. Rapid generation of durable B cell memory to SARS-
658 CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. *Sci Immunol* 2020; **5**(54).
659 33. Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 infection induces long-lived bone marrow
660 plasma cells in humans. *Nature* 2021; **595**(7867): 421-5.
661 34. Peghin M, De Martino M, Fabris M, et al. The Fall in Antibody Response to SARS-CoV-2: a
662 Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery. *J Clin*
663 *Microbiol* 2021; **59**(11): e0113821.
664 35. Muena NA, García-Salum T, Pardo-Roa C, et al. Induction of SARS-CoV-2 neutralizing antibodies
665 by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals. *eBioMedicine*
666 2022; **78**.
667 36. Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2.
668 *Science (New York, NY)* 2020; **369**(6499): 77-81.
669 37. Dashdorj NJ, Wirz OF, Roltgen K, et al. Direct comparison of antibody responses to four SARS-
670 CoV-2 vaccines in Mongolia. *Cell Host Microbe* 2021; **29**(12): 1738-43 e4.
671 38. Silva SJRd, Kohl A, Pena L, Pardee K. Recent insights into SARS-CoV-2 omicron variant. 2023;
672 **33**(1): e2373.
673 39. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.
674 *Lancet* 2021; **398**(10317): 2126-8.
675 40. Quandt J, Muik A, Salisch N, et al. Omicron BA.1 breakthrough infection drives cross-variant
676 neutralization and memory B cell formation against conserved epitopes. *Sci Immunol* 2022; **7**(75):
677 eabq2427.

678 41. Kaku CI, Bergeron AJ, Ahlm C, et al. Recall of preexisting cross-reactive B cell memory after
679 Omicron BA.1 breakthrough infection. *Sci Immunol* 2022; **7**(73): eabq3511.
680 42. Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant neutralizing
681 antibodies elicited by SARS-CoV-2 infection. *Science* 2021; **372**(6549): 1413-8.
682 43. Gallian P, Brisbarre N, Nurtop E, et al. Low neutralization capacity against SARS-CoV-2 Omicron
683 BQ.1.1 of convalescent plasma collected during circulation of Omicron BA.1. *Vox Sang* 2023; **118**(5):
684 407-8.
685 44. Viboud C, Epstein SL. First flu is forever. *Science* 2016; **354**(6313): 706-7.
686 45. Monto AS, Malosh RE, Petrie JG, Martin ET. The Doctrine of Original Antigenic Sin: Separating
687 Good From Evil. *J Infect Dis* 2017; **215**(12): 1782-8.
688 46. Giovanetti M, Fonseca V, Wilkinson E, et al. Replacement of the Gamma by the Delta variant
689 in Brazil: Impact of lineage displacement on the ongoing pandemic. *Virus Evol* 2022; **8**(1): veac024.

690



Figure 1: Prevalence of anti-SARS-CoV-2 Spike S1 and -NCP antibodies in Bolivia as October 2021 and June 2022.

The prevalence of anti-SARS-CoV-2 Spike S1 (A, C) and -NCP (B, D) antibodies was reported for each department in Bolivia and nationwide as October 2021 (A, B) and June 2022 (C, D).



Figure 2: Prevalence of neutralizing anti-SARS-CoV-2 antibodies in Bolivia as October 2021 and June 2022.
The prevalence of neutralizing antibodies was reported for each department in Bolivia and nationwide for the D614G (A, E), Gamma (B, F), Delta (C, G) and Omicron BA.1 (D, H) variants as October 2021 (upper panel: A, B, C, D) and June 2022 (lower panel: E, F, G, H). The prevalence was obtained with the positivity cut-off ≥640.



Figure 3: Variant circulation in Bolivia as October 2021 and June 2022.
Percentage of the population exhibiting titers for Gamma, Delta, and Omicron BA.1 being at least equivalent to (log2-ratios ≤0, upper panel: A, B, C, D), twice (log2-ratios ≤-1, middle panel: E, F, G, H), or four times (log2-ratios ≤-2, lower panel: I, J, K, L) that of D614G are presented for each department of Bolivia. Results for D614G/γ are depicted in blue as October 2021 (A, E, I) and June 2022 (B, F, J). Results obtained as June 2022 for D614G/δ and for D614G/o are depicted in green (C, G, K) and in red (D, H, L), respectively. D614G: ancestral D614G variant; γ: Gamma variant; δ: Delta variant; o: Omicron BA.1 variant.



Figure 4: Quantification of SARS-CoV-2 circulating antigenic groups in Bolivia by Average titer method as October 2021 and as June 2022.

Percentage of the population in each department presenting a neutralizing antibody response against a defined antigenic group, including the GI (green), GII (blue), GIII (red), using the Average titer method.

For antigenic group assignment by VNT, D614G and Delta variants were cluster in to the antigenic group I (GI), antigenic group II (GII) corresponded to the Gamma variant, while antigenic group III (GIII) was defined by the Omicron BA.1 variant (see methods for details). For evaluating genomic data, the prevalences of GI (from ancestral, Alpha, Delta, Lambda, and Epsilon variants; light-green), the prevalences of GII (from Beta, Gamma, Mu, Iota, and Zeta variants; light-blue), and the prevalences of GIII (from all Omicron-derived variants; light-red) were obtained for neighboring countries of Bolivia using publicly accessible genomic data when available.